Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care Abo

On June 23, 2026, Stacy Markel, Chief People Officer at Nuvation Bio Inc. (NYSE:NUVB), exercised 125,000 options for Class A Common Stock and sold the resulting shares for a transaction value of approximately $753,000, according to the SEC Form 4 filing.

Post-transaction Class A common shares (direct)

Post-transaction value (direct ownership)

Transaction value based on SEC Form 4 weighted average purchase price ($6.03); post-transaction value based on June 23, 2026 market close (value: $196,849.64).

What was the structure and economic rationale of this insider sale?This transaction involved the exercise of 125,000 stock options immediately followed by the sale of the resulting Class A shares, providing liquidity while converting derivative holdings into cash without affecting indirect or trust-held interests.

How materially did the sale alter Markel Stacy's equity exposure to Nuvation Bio Inc?The direct Class A position was reduced by 79.32%, with 32,591 shares remaining, but Markel continues to control 629,810 options outstanding, which, if exercised, could significantly restore equity exposure.

Did the trade occur under a pre-established plan?Yes, the shares were sold pursu

Fuente original: Yahoo Finance (https://finance.yahoo.com/markets/stocks/articles/nuvation-bio-stock-190-despite-233905667.html)